Home
Regeneron and Sanofi: FDA Approves Dupixent® as First Treatment for Eosinophilic Esophagitis

Regeneron and Sanofi: FDA Approves Dupixent® as First Treatment for Eosinophilic Esophagitis

Impacting News May 23, 2022

Regeneron Pharmaceuticals and Sanofi Announce FDA Approval of Dupixent®
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. FDA has approved Dupixent (dupilumab . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
,
May 23, 2022

Other Articles